In the earnings call transcript of previous quarter published at Seeking Alpha, the CEO of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Justin Gover, updated on management changes. More recently, the firm engaged Scott Giacobello as its new CFO. Giacobello also participated in the conference call and released financial overview of the previous quarter.
Scott has wide-ranging operational and financial experience of over 25 years. He is a proficient executive who was CFO for Chase Pharmaceuticals Corporation.
In expectation of the approval for and release of Epidiolex with GW Pharmaceuticals stock now trading on NASDAQ, the management plans to transition into a U.S. domestic registrant reporting firm as per U.S. GAAP in coming period. Scott’s extensive accounting and financial proficiency will be of value as the firm undergoes this transition.
Adam George, the ex CFO of GW Pharmaceuticals, has been engaged as firm’s Managing Director, UK. These key changes come to support firm’s UK operations and accomplish planned operating and strategic objectives, which constitute manufacturing scale up, expansion of product pipeline. George is helping Scott so as to make him comfortable through the CFO evolution process.
These vital leadership engagements exhibit GW Pharmaceuticals’ continued progression into a trans-Atlantic commercial phased biopharma entity. The company also confirmed about the resignation of Stephen Wright that is planned for this month.
Although last earnings call was his last conference call in his capacity as CMO, Wright will continue to play a key role as a senior medical advisor to firm, with utmost emphasis on the Epidiolex NDA submission and European regulatory application.
Earlier the company updated about the engagement of Volker Knappertz as its Chief Medical Officer. With reporting to firm’s CEO, the new CMO will work from the firm’s U.S. headquarters. Additionally, the firm said that it has engaged Professor Ben Whalley as the Head of Discovery Research.